MSI Methylation Sciences Inc.




15300 Croydon Drive Suite 300

Surrey, BC V3S 0Z5 Canada


Member Sector: Biopharmaceuticals

Methylation Sciences (“MSI” or the “Company”) is focused on developing new products based on molecules which have clinical proof of concept but have yet to be exploited in the major pharmaceutical markets. The Company’s first product, STRADAâ„¢, is based on S-adenosyl methionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. The Company has developed superior oral formulations of this molecule with STRADA being the first in clinical development. MSI has a broad intellectual property portfolio and pipeline of candidates.